Growth Factors

  • Henning SchliephakeEmail author
  • Florian Böhrnsen


In the human body, growth factors are soluble signalling molecules that contribute to tissue formation and regeneration. Their potential use in tissue engineering has been explored in numerous clinical and preclinical studies. Most of the growth factors currently considered are involved in the regeneration of mesenchymal and vascular tissues. Autogenous growth factors derived from platelet concentrates have shown to support soft tissue healing in dentoalveolar reconstructive procedures. Recombinant growth factors such as rhPDGF-BB and rhFGF-2 appear to be useful for the improvement of outcomes of periodontal treatment; the evidence for beneficial effects of rhPDGF-BB in ridge augmentation is yet very limited. The use of BMPs in ridge augmentation has shown some potential, although no controlled trials have clearly shown a beneficial effect over standard treatment yet. The effect of BMPs in sinus lift procedures has been very limited due to the high intrinsic regenerative capacity of this site, whereas the efficacy of rhBMP-2 in cleft repair has been satisfactory. Repair of larger bone defects such as segmental reconstruction appears to be limited to sites with uncompromised biology and unrestricted regenerative capacity. Innovative approaches with respect to sophisticated carrier technology and multiple growth factor delivery still have to await thorough preclinical testing and regulatory approval.


Growth factors Tissue engineering Platelet concentrates Bone morphogenetic protein Platelet-derived growth factor Bone regeneration Periodontal healing Soft tissue healing 


  1. 1.
    Madjidinia Sadeghpour A, Yousefi B. The roles of signaling pathways in bone repair and regeneration. J Cell Physiol. 2018;233:2937–48.PubMedCrossRefGoogle Scholar
  2. 2.
    Charoenlarp P, Rajendran AK, Iseki S. Role of fibroblast growth factors in bone regeneration. Inflamm Regen. 2017;37:10.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Morikawa M, Derynck R, Nickel MK, et al. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):1–24.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Nickel J, Ten Dijke P, Mueller TD. TGF-β family co-receptor function and signaling. Acta Biochim Biophys Sin (Shanghai). 2018;50(1):12–36.CrossRefGoogle Scholar
  5. 5.
    Dai J, Rabie AB. VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res. 2007;86:937–50.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22:233–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Balmayor ER. Targeted delivers as key for success of small osteoinductive molecules. Adv Drug Deliv Rev. 2015;94:13–27.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Gothard D, Smith EL, Kanczler JM, Rashidi H, Qutachi O, Henstock J, Rotherham M, El Haj A, Shakesheff KM, Oreffo RO. Tissue engineered bone using select growth factors: a comprehensive review of animal studies and clinical translation studies in man. Eur Cell Mater. 2014;28:166–20.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Dohan-Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte and platelet-rich fibrin (L-PRF). Cell. 2009;27:158–67.Google Scholar
  10. 10.
    Masuki H, Okudera T, Watanebe T, Suzuki M, Jishiyama K, Okudera H, Nakata K, Uematsu K, Su CY, Kawase T. Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). Int J Implant Dent. 2016;2:19–5.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Weibrich G, Kleis WKG, Hafner G, Hirzler WE. Growth factor levels in platelet-rich plasma and correlation with donor age, sex and platelet count. J Craniomaxillofac Surg. 2002;30:97–102.PubMedCrossRefGoogle Scholar
  12. 12.
    Anitua E, Andia I, Sanchez M. PRGF (plasma rich in growth factors). Dent Dialog. 2004;3:4–15.Google Scholar
  13. 13.
    Kobayashi E, Flückiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, Miron RJ. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 2016;20(9):2353–60.CrossRefGoogle Scholar
  14. 14.
    Schliephake H, Vucak M, Boven J, Backhaus S, Annen T, Epple M. Solvent free production of porous PDLLA/calcium carbonate composite scaffolds improves the release of bone growth factors. Oral Maxillofac Surg. 2015;19:133–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Stähli A, Strauss FJ, Gruber R. The use of platelet-rich-plasma to enhance the outcomes of implant-related therapies: a systematic review. Clin Oral Implants Res. 2018;29(Suppl 18):20–36.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Strauss FJ, Stähli A, Gruber R. The use of platelet-rich-fibrin to enhance the outcomes of implant-related therapies: a systematic review. Clin Oral Implants Res. 2018;29(Suppl 18):6–19.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Schliephake H. Drugs and diseases. Summary and consensus statements. The 5th EAO Consensus Conference 2018. Clin Oral Implants Res. 2018;29(Suppl 18):93–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:638–46.CrossRefGoogle Scholar
  19. 19.
    Castillo-Cardiel G, Medina-Quintana VM, Lomelí-Enríquez M, Medrano-Muñoz F, Guerrero-Velázquez C, Contreras-López CK, Fuentes-Orozco C, Irusteta-Jiménez L, Michel-Espinoza LR, González-Ojeda A. Platelet-rich plasma and its effect in bone regeneration in mandibular fractures. Controlled clinical trial. Gac Med Mex. 2017;153(4):459–65.PubMedGoogle Scholar
  20. 20.
    Darby IB, Morris KH. A systematic review of the use of growth factors in human periodontal regeneration. J Periodontol. 2013;84:465–76.PubMedCrossRefGoogle Scholar
  21. 21.
    Li F, Yu F, Xu X, Li C, Huang D, Zhou X, Ye L, Zheng L. Evaluation of recombinant human FGF-2 and PDGF-BB in periodontal regeneration: a systematic review and meta-analysis. Sci Rep. 2017;7:65.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Solchaga LA, Daniels T, Roach S, Beasley W, Snel LB. Effect of implantation of Augment(®) Bone Graft on serum concentrations of platelet-derived growth factors: a pharmacokinetic study. Clin Drug Investig. 2013;33:143–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Khoshkam V, Chan HL, Lin GH, Mailoa J, Giannobile WV, Wang HL, Oh TJ. Outcomes of regenerative treatment with rhPDGF-BB and rhFGF-2 for periodontal intra-bony defects: a systematic review and meta-analysis. J Clin Periodontol. 2015;42(3):272–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Santana RB, Santana CM. A clinical comparison of guided bone regeneration with platelet-derived growth factor-enhanced bone ceramic versus autogenous bone block grafting. Int J Oral Maxillofac Implants. 2015;30:700–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Cochran DL, Oh TJ, Mills MP, Clem DS, McClain PK, Schallhorn RA, McGuire MK, Scheyer ET, Giannobile WV), Reddy MS, Abou-Arraj RV, Vassilopoulos PJ, Genco RJ, Geurs NC, Takemura A. A randomized clinical trial evaluating rh-FGF-2/β-TCP in periodontal defects. J Dent Res 2016;95(5):523–530.PubMedCrossRefGoogle Scholar
  26. 26.
    Devi R, Dixit J. Clinical evaluation of insulin like growth factor-I and vascular endothelial growth factor with alloplastic bone graft material in the management of human two wall intra-osseous defects. J Clin Diagn Res. 2016;10(9):ZC41–6.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Freitas RM, Spin-Neto R, Marcantonio Junior E, Pereira LA, Wikesjö UM, Susin C. Alveolar ridge and maxillary sinus augmentation using rhBMP-2: a systematic review. Clin Implant Dent Relat Res. 2015;17(Suppl 1):e192–201.PubMedCrossRefGoogle Scholar
  28. 28.
    Kelly MP, Vaughn OL, Anderson PA. Systematic review and meta-analysis of recombinant human bone morphogenetic protein-2 in localized alveolar ridge and maxillary sinus augmentation. J Oral Maxillofac Surg. 2016;74:928–39.PubMedCrossRefGoogle Scholar
  29. 29.
    Schliephake H. Clinical efficacy of growth factors to enhance tissue repair in oral and maxillofacial reconstruction: a systematic review. Clin Implant Dent Relat Res. 2015;17(2):247–73.PubMedCrossRefGoogle Scholar
  30. 30.
    Wu C, Pan W, Feng C, Su Z, Duan Z, Zheng Q, Hua C, Li C. Grafting materials for alveolar cleft reconstruction: a systematic review and best-evidence synthesis. Int J Oral Maxillofac Surg. 2018;47(3):345–56.PubMedCrossRefGoogle Scholar
  31. 31.
    Riley P, Glenny AM, Worthington HV, Littlewood A, Fernandez Mauleffinch LM, Clarkson JE, McCabe MG. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors. Cochrane Database Syst Rev. 2017;11:CD011990. Scholar
  32. 32.
    Kim YJ, Lee JY, Kim JE, Park JC, Shin SW, Cho KS. Ridge preservation using demineralized bone matrix gel with recombinant human bone morphogenetic protein-2 after tooth extraction: a randomized controlled clinical trial. J Oral Maxillofac Surg. 2014;72:1281–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Glowacki J. Demineralized bone and BMPs: basic science and clinical utility. J Oral Maxillofac Surg. 2015;73(Suppl):S126–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976). 2006;31(24):2813–9.CrossRefGoogle Scholar
  35. 35.
    Buttermann GR. Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion. Spine J. 2008;8:426–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Singh K, Ahmadinia K, Park DK, Nandyala SV, Marquez-Lara A, Patel AA, Fineberg SJ. Complications of spinal fusion with utilization of bone morphogenetic protein: a systematic review of the literature. Spine (Phila Pa 1976). 2014;39:91–101.CrossRefGoogle Scholar
  37. 37.
    Boyne PJ, Lilly LC, Marx RE, et al. De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg. 2005;63:1693–707.PubMedCrossRefGoogle Scholar
  38. 38.
    Fiorellini JP, Howell TH, Cochran D, et al. Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. J Periodontol. 2005;76:605–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderstone RA. Clinical and radiographic outcomes of anterior limbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine. 2002;27:2396–408.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Leknes KN, Yang J, Qahash M, Polimeni G, Susin C, Wikesjö UM. Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: radiographic observations. Clin Oral Implants Res. 2008;19:1027–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Sauerborn M, van de Vosse E, Delawi D, van Dissel JT, Brinks V, Schellekens H. Natural antibodies against bone morphogenic proteins and interferons in healthy donors and in patients with infections linked to type-1 cytokine responses. J Interf Cytokine Res. 2011;31:661–9.CrossRefGoogle Scholar
  42. 42.
    Burkus JK, Gornet MF, Schuler TC, Kleeman TJ, Zdeblick TA. Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2. J Bone Joint Surg Am. 2009;91:1181–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Hwang CJ, Vaccaro AR, Lawrence JP, Hong J, Schellekens H, Alaoui-Ismaili MH, Falb DJ. Immunogenicity of bone morphogenetic proteins. J Neurosurg Spine. 2009;10(5):443–51.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, Helfand M. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158(12):890–902.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Pountos I, Panteli M, Georgouli T, Giannoudis PV. Neoplasia following use of BMPs: is there an increased risk? Expert Opin Drug Saf. 2014;13(11):1525–34.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    FDA Executive Summary, Document No. P050053. 4 Oct 2006.Google Scholar
  47. 47.
    Uludag H, D’Augusta D, Palmer R, Timony G, Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res. 1999;46:193–202.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Schliephake H, Scharnweber D. Chemical and biological functionalization of titanium for dental implants. J Mater Chem. 2008;18:2404–14.CrossRefGoogle Scholar
  49. 49.
    Schliephake H. Application of bone growth factors—the potential of different carrier systems. Oral Maxillofac Surg. 2010;14(1):17–22.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Schliephake H, Bötel C, Förster A, Schwenzer B, Reichert J, Scharnweber D. Effect of oligonucleotide mediated immobilization of bone morphogenic proteins on titanium surfaces—an in vitro study. Biomaterials. 2012;33:1315–22.PubMedCrossRefGoogle Scholar
  51. 51.
    Guillot R, Gilde F, Becquart P, Sailhan F, Lapeyrere A, Logeart-Avramoglou D, Picart C. The stability of BMP loaded polyelectrolyte multilayer coatings on titanium. Biomaterials. 2013;34(23):5737–46.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Gruber RM, Krohn S, Mauth C, Dard M, Molenberg A, Lange K, Perske C, Schliephake H. Mandibular reconstruction using a calcium phosphate/polyethylene glycol hydrogel carrier with BMP-2. J Clin Periodontol. 2014;41:820–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Geuze RE, Theyse LF, Kempen DH, Hazewinkel HA, Kraak HY, Oner FC, Dhert WJ, Alblas J. A differential effect of bone morphogenetic protein-2 and vascular endothelial growth factor release timing on osteogenesis at ectopic and orthotopic sites in a large-animal model. Tissue Eng Part A. 2012;18(19–20):2052–62.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Moser N, Lohse N, Golstein J, Kauffmann P, Sven B, Epple M, Schliephake H. Do we need retarded delivery of bone growth factors in facial bone repair? An experimental study in rats. Eur Cell Mater. 2017;34:162–79.PubMedCrossRefGoogle Scholar
  55. 55.
    Bayer EA, Gottardi R, Fedorchak MV, Little SR. The scope and sequence of growth factor delivery for vascularized bone tissue regeneration. J Control Release. 2015;219:129–40.PubMedCrossRefGoogle Scholar
  56. 56.
    Howell TH, Fiorellini JP, Paquette DW, Ofenbacher S, Giannobile WV, Lynch SE. A phase I/II trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J Periodontal Res. 1997;68:1186–93.CrossRefGoogle Scholar
  57. 57.
    Jazayeri HE, Tahriri M, Razavi M, Khoshroo K, Fahimipour F, Dashtimoghadam E, Almeida L, Tayebi L. A current overview of materials and strategies for potential use in maxillofacial tissue regeneration. Mater Sci Eng C Mater Biol Appl. 2017;70:913–29.PubMedCrossRefGoogle Scholar
  58. 58.
    Hernández A, Reyes R, Sánchez E, Rodríguez-Évora M, Delgado A, Evora C. In vivo osteogenic response to different ratios of BMP-2 and VEGF released from a biodegradable porous system. J Biomed Mater Res A. 2012;100(9):2382–91.PubMedGoogle Scholar
  59. 59.
    Young S, Patel ZS, Kretlow JD, Murphy MB, Mountziaris PM, Baggett LS, Ueda H, Tabata Y, Jansen JA, Wong M, Mikos AG. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. Tissue Eng Part A. 2009;15(9):2347–62.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Lohse N, Moser N, Backhaus S, Annen T, Epple M, Schliephake H. Continuous delivery of rhBMP2 and rhVEGF165 at a certain ration enhances bone formation in mandibular defects over the delivery of rhBMP2 alone—an experimental study in rats. J Control Release. 2015;220:201–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Moser N, Goldstein J, Kauffmann P, Epple M, Schliephake H. Experimental variation of the level and the ratio of angiogenic and osteogenic signaling affects the spatiotemporal expression of bone-specific markers and organization of bone formation in ectopic sites. Clin Oral Investig. 2018;22(3):1223–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Oral and Maxillofacial SurgeryUniversity of GöttingenGöttingenGermany

Personalised recommendations